SuperworthJazz Pharmaceuticals profit margin JAZZ
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 20.4%
- Operating margin, 12 months
- 19.5%
- Net margin on a year earlier
- +30.4 pts
- Peer median
- 9.0%
Over the twelve months to Jun 30, 2026, Jazz Pharmaceuticals kept 20.4% of its revenue as net profit, with an operating margin of 19.5%.
Five years earlier its net margin was 1.5%.
The median for 10 large drugmakers of a similar size is 9.0%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin |
|---|---|---|
| FY2025 | −8.3% | −10.1% |
| FY2024 | 13.8% | 17.6% |
| FY2023 | 10.8% | 15.1% |
| FY2022 | −6.1% | −1.8% |
| FY2021 | −10.7% | 5.5% |
| FY2020 | 10.1% | 16.0% |
| FY2019 | 24.2% | 24.6% |
| FY2018 | 23.6% | 32.5% |
| FY2017 | 30.1% | 32.7% |
| FY2016 | 26.7% | 39.8% |
| FY2015 | 24.9% | 38.4% |
| FY2014 | 5.0% | 16.7% |
| FY2013 | 24.8% | 39.0% |
| FY2012 | 49.2% | 33.8% |
| FY2011 | 45.9% | 46.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 20.4% | +30.4 pts | 19.5% | |
| Q1 FY26 | 0.7% | −11.2 pts | −0.9% | |
| Q4 FY25 | −8.3% | −22.1 pts | −10.1% | |
| Q3 FY25 | −8.9% | −20.5 pts | −11.9% | |
| Q2 FY25 | −9.9% | −20.0 pts | −7.1% | |
| Q1 FY25 | 11.9% | +3.3 pts | 14.6% | |
| Q4 FY24 | 13.8% | +2.9 pts | 17.6% | |
| Q3 FY24 | 11.6% | +9.5 pts | 16.2% | |
| Q2 FY24 | 10.1% | +12.4 pts | 14.3% | |
| Q1 FY24 | 8.6% | +12.8 pts | 13.5% | |
| Q4 FY23 | 10.8% | +16.9 pts | 15.1% | |
| Q3 FY23 | 2.1% | +2.6 pts | 5.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Jazz Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| JAZZJazz Pharmaceuticals | 20.4% |
| BMRNBiomarin Pharmaceutical | 2.1% |
| CORTCorcept Therapeutics | 6.6% |
| PTGXProtagonist Therapeutics | 29.4% |
| TGTXTG Therapeutics | 55.2% |
| ALKSAlkermes plc. | 4.0% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| BIIBBiogen | 8.3% |
| INDVIndivior Pharmaceuticals | 26.7% |
| Peer median | 9.0% |
Where Jazz Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Jazz Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.